C4 THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.16 USD | -9.41% |
|
-8.61% | +9.03% |
| May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
| May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,426 | 1,566 | 288.8 | 278.4 | 423.8 | - | - |
| Enterprise Value (EV) 1 | 1,064 | 1,500 | 21.89 | 24.76 | 126.5 | 94.39 | -0.5921 |
| P/E ratio | -21.5 x | -17.7 x | -2.25 x | -2.12 x | -3.72 x | -3.26 x | -4.97 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 42.9 x | 34.2 x | 9.29 x | 13.4 x | 14.6 x | 16.8 x | 11.8 x |
| EV / Revenue | 32.1 x | 32.8 x | 0.7 x | 1.19 x | 4.37 x | 3.75 x | -0.02 x |
| EV / EBITDA | -19.2 x | -25.4 x | -0.22 x | -0.23 x | -1.62 x | -1.14 x | 0.01 x |
| EV / FCF | -15.7 x | -17 x | -0.2 x | -0.23 x | -1.17 x | -0.77 x | 0 x |
| FCF Yield | -6.38% | -5.88% | -509% | -438% | -85.5% | -130% | 22,572% |
| Price to Book | 5.08 x | 4.02 x | 1 x | 1.39 x | 1.76 x | 2.48 x | 1.68 x |
| Nbr of stocks (in thousands) | 43,030 | 48,626 | 48,957 | 49,281 | 68,806 | - | - |
| Reference price 2 | 33.13 | 32.20 | 5.900 | 5.650 | 6.160 | 6.160 | 6.160 |
| Announcement Date | 3/11/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 21.38 | 33.2 | 45.78 | 31.1 | 20.76 | 28.97 | 25.2 | 35.78 |
| EBITDA 1 | - | -55.4 | -59.13 | -97.84 | -109.9 | -78.08 | -83.16 | -74.18 |
| EBIT 1 | - | -60.45 | -82.13 | -129.5 | -139 | -121.3 | -143.5 | -126 |
| Operating Margin | - | -182.1% | -179.39% | -416.56% | -669.84% | -418.49% | -569.35% | -352.09% |
| Earnings before Tax (EBT) 1 | - | -66.96 | -83.89 | -128.2 | -131.2 | -122.4 | -148.1 | -138.8 |
| Net income 1 | - | -66.34 | -83.89 | -128.2 | -132.5 | -122.8 | -149.3 | -142.3 |
| Net margin | - | -199.83% | -183.23% | -412.19% | -638.34% | -423.66% | -592.65% | -397.69% |
| EPS 2 | -3.670 | -1.542 | -1.820 | -2.620 | -2.670 | -1.655 | -1.891 | -1.238 |
| Free Cash Flow 1 | - | -67.9 | -88.24 | -111.4 | -108.5 | -108.2 | -123 | -133.6 |
| FCF margin | - | -204.55% | -192.73% | -358.36% | -522.96% | -373.26% | -488.33% | -373.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 9/10/20 | 3/11/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.08 | 7.654 | 13.83 | 6.754 | 2.854 | 3.759 | 2.664 | 11.07 | 3.261 | 3.039 | 4.74 | 5.625 | 4.52 | - | - |
| EBITDA 1 | -8.579 | -31.06 | -26.95 | -32.07 | -30.85 | -35.68 | -30.68 | -27.36 | -30.64 | -29.33 | -23.31 | -20.65 | -23.75 | - | - |
| EBIT 1 | -15.26 | -31.37 | -27.38 | -32.49 | -38.29 | -36.23 | -37.57 | -27.81 | -37.43 | -29.78 | -31.43 | -29.9 | -36.5 | - | - |
| Operating Margin | -75.98% | -409.84% | -197.95% | -481.02% | -1,341.73% | -963.77% | -1,410.21% | -251.16% | -1,147.72% | -979.99% | -663.02% | -531.48% | -807.43% | - | - |
| Earnings before Tax (EBT) 1 | -15.66 | -31.62 | -27.41 | -31.96 | -37.18 | -34.78 | -35.92 | -26.03 | -34.48 | -28.36 | -28 | -25.3 | -35.3 | - | - |
| Net income 1 | -15.66 | -31.62 | -27.41 | -31.96 | -37.18 | -34.78 | -35.92 | -27.04 | -34.75 | -28.36 | -31.32 | -30.1 | -36.73 | - | - |
| Net margin | -77.99% | -413.12% | -198.15% | -473.17% | -1,302.91% | -925.25% | -1,348.42% | -244.19% | -1,065.75% | -933.23% | -660.66% | -535.13% | -812.55% | - | - |
| EPS 2 | -0.3100 | -0.6500 | -0.5600 | -0.6500 | -0.7600 | -0.7100 | -0.7300 | -0.5500 | -0.6800 | -0.4100 | -0.3982 | -0.3805 | -0.4670 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/8/23 | 11/1/23 | 2/22/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 362 | 65.4 | 267 | 254 | 297 | 329 | 424 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -67.9 | -88.2 | -111 | -109 | -108 | -123 | -134 |
| ROE (net income / shareholders' equity) | - | - | -25% | -37.8% | -49.5% | -35.5% | -44.2% | -25% |
| ROA (Net income/ Total Assets) | - | - | -18.5% | -27.3% | -32.8% | -30.4% | -64.8% | -27.8% |
| Assets 1 | - | - | 453.5 | 468.8 | 403.6 | 404.4 | 230.6 | 511.9 |
| Book Value Per Share 2 | - | 6.520 | 8.000 | 5.920 | 4.070 | 3.500 | 2.480 | 3.660 |
| Cash Flow per Share 2 | - | - | -1.890 | -2.170 | -2.150 | 0.3300 | -2.700 | -0.3700 |
| Capex 1 | - | 0.65 | 1.28 | 5.5 | 1.71 | 2.33 | 3.23 | 3.78 |
| Capex / Sales | - | 1.96% | 2.79% | 17.67% | 8.23% | 8.05% | 12.82% | 10.58% |
| Announcement Date | 9/10/20 | 3/11/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.16
USD
Average target price
11.88
USD
Spread / Average Target
+92.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.03% | 424M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CCCC Stock
- Financials C4 Therapeutics, Inc.
